Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Valentina Lorenzoni, Leopoldo Trieste & Giuseppe Turchetti. (2015) The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 611-624.
Read now
Read now
Gregory Hill, Richard Barron, Kelly Fust, Michelle E. Skornicki, Douglas C. A. Taylor, Milton C. Weinstein & Gary H. Lyman. (2014) Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. Journal of Medical Economics 17:1, pages 32-42.
Read now
Read now
Vasily Belozeroff, Andrew Lee, Spring Tseng, Silvia Chiroli & Jonathan D. Campbell. (2013) Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. Journal of Medical Economics 16:9, pages 1154-1162.
Read now
Read now
Rob Boer, Anjana M. Lalla & Vasily Belozeroff. (2012) Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. Journal of Medical Economics 15:3, pages 509-520.
Read now
Read now
Gary Lyman, Anjana Lalla, Richard Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 25:2, pages 401-411.
Read now
Read now
Articles from other publishers (27)
Melanie L.R. Wyld, Nicole L. De La Mata, Andrea Viecelli, Ramyasuda Swaminathan, Kim M O'Sullivan, Emma O'Lone, Matthew Rowlandson, Anna Francis, Kate Wyburn & Angela C. Webster. (2022) Sex-Based Differences in Risk Factors and Complications of Chronic Kidney Disease. Seminars in Nephrology 42:2, pages 153-169.
Crossref
Crossref
Lihua Xie, Xuantao Hu, Wenzhao Li & Zhengxiao Ouyang. (2021) A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures. BMC Nephrology 22:1.
Crossref
Crossref
Sofie K. Nordvåg, Marit D. Solbu, Toralf Melsom, Frida I. Nissen, Camilla Andreasen, Tove T. Borgen, Bjørn O. Eriksen, Ragnar M. Joakimsen & Åshild Bjørnerem. (2021) Estimated Glomerular Filtration Rate (eGFR) based on cystatin C was associated with increased risk of hip and proximal humerus fractures in women and decreased risk of hip fracture in men, whereas eGFR based on creatinine was not associated with fracture risk in both sexes: The Tromsø Study. Bone 148, pages 115960.
Crossref
Crossref
Yunyun Zhu, Jingtao Hu, Wenlun Han, Jianwei Lu & Yuqing Zeng. (2020) Simultaneous bilateral femoral neck fractures in a dialysis-dependent patient: case report and literature review. BMC Musculoskeletal Disorders 21:1.
Crossref
Crossref
N. A. Goto, A. C. G. Weststrate, F. M. Oosterlaan, M. C. Verhaar, H. C. Willems, M. H. Emmelot-Vonk & M. E. Hamaker. (2019) The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. Osteoporosis International 31:1, pages 13-29.
Crossref
Crossref
Dorey A. Glenn & Michelle R. Denburg. (2019) Bone Health in Glomerular Kidney Disease. Current Osteoporosis Reports 17:6, pages 570-579.
Crossref
Crossref
H. Chen, P. Lips, M. G. Vervloet, N. M. van Schoor & R. T. de Jongh. (2018) Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam. Osteoporosis International 29:9, pages 2129-2138.
Crossref
Crossref
Myoung-Hee Kim, Yong Chul Kim, Jung Pyo Lee, Ho Kim, Dong Ki Kim, Dong-Ryeol Ryu, Seung Seok Han, Jeonghwan Lee, Yong-Lim Kim, Shin-Wook Kang, Jang-Hee Cho & Yon Su Kim. (2018) Three-year income trends in Korean adults commencing haemodialysis: A prospective cohort. Nephrology 23:7, pages 625-632.
Crossref
Crossref
Michelle Denburg & Thomas L. Nickolas. (2018) Declining Hip Fracture Rates in Dialysis Patients: Is This Winning the War?. American Journal of Kidney Diseases 71:2, pages 154-156.
Crossref
Crossref
E. Elbasha, W. Greaves, D. Roth & C. Nwankwo. (2017) Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. Journal of Viral Hepatitis 24:4, pages 268-279.
Crossref
Crossref
A.-j. Chang, Q. Ying, X.-n. Chen, W.-m. Wang & N. Chen. (2016) Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis. Osteoporosis International 27:12, pages 3599-3606.
Crossref
Crossref
James Amis. (2016) The Split Second Effect: The Mechanism of How Equinus Can Damage the Human Foot and Ankle. Frontiers in Surgery 3.
Crossref
Crossref
Michelle R. Denburg. (2016) Skeletal manifestations of renal disease in childhood. Current Opinion in Nephrology and Hypertension 25:4, pages 292-300.
Crossref
Crossref
Michelle R. Denburg, Juhi Kumar, Thomas Jemielita, Ellen R. Brooks, Amy Skversky, Anthony A. Portale, Isidro B. Salusky, Bradley A. Warady, Susan L. Furth & Mary B. Leonard. (2016) Fracture Burden and Risk Factors in Childhood CKD. Journal of the American Society of Nephrology 27:2, pages 543-550.
Crossref
Crossref
Vasily Belozeroff, Glenn M. Chertow, Christopher N. Graham, Bastian Dehmel, Patrick S. Parfrey & Andrew H. Briggs. (2015) Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health 18:8, pages 1079-1087.
Crossref
Crossref
Henry J. Henk, Carly J. Paoli & Shravanthi R. Gandra. (2015) A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia. Advances in Therapy 32:11, pages 1104-1116.
Crossref
Crossref
María José Pérez-Sáez, Daniel Prieto-Alhambra, Clara Barrios, Marta Crespo, Dolores Redondo, Xavier Nogués, Adolfo Díez-Pérez & Julio Pascual. (2015) Increased hip fracture and mortality in chronic kidney disease individuals: The importance of competing risks. Bone 73, pages 154-159.
Crossref
Crossref
Charu Gupta, Glenn M. Chertow, Mark T. Linthicum, Karen Van Nuys, Vasily Belozeroff, Darryl Quarles & Darius N. Lakdawalla. (2014) Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism. Health Services Research, pages n/a-n/a.
Crossref
Crossref
Thomas J. Arneson, Shuling Li, Jiannong Liu, Ryan D. Kilpatrick, Britt B. Newsome & Wendy L. St. Peter. (2013) Trends in Hip Fracture Rates in US Hemodialysis Patients, 1993-2010. American Journal of Kidney Diseases 62:4, pages 747-754.
Crossref
Crossref
Roland J. Thorpe, Patrick Richard, Janice V. Bowie, Thomas A. Laveist & Darrell J. Gaskin. (2013) Economic Burden of Men's Health Disparities in the United States. International Journal of Men's Health 12:3, pages 195-212.
Crossref
Crossref
Meghan J. Elliott, Matthew T. James, Robert R. Quinn, Pietro Ravani, Marcello Tonelli, Luz Palacios-Derflingher, Zhi Tan, Braden J. Manns, Gregory A. Kline, Paul E. Ronksley & Brenda R. Hemmelgarn. (2013) Estimated GFR and Fracture Risk. Clinical Journal of the American Society of Nephrology 8:8, pages 1367-1376.
Crossref
Crossref
Nikos Maniadakis, Georgia Kourlaba, Dennis V. Cokkinos, Aggeliki Angeli & John Kyriopoulos. (2012) The economic burden of atherothrombosis in Greece: results from the THESIS study. The European Journal of Health Economics 14:4, pages 655-665.
Crossref
Crossref
Lia Gentil, Alain Vanasse & Marianne Xhignesse. (2013) Episódios de cuidados: um conceito em saúde pública. Ciência & Saúde Coletiva 18:1, pages 138-144.
Crossref
Crossref
Thomas A. LaVeist, Darrell Gaskin & Patrick Richard. (2011) Estimating the Economic Burden of Racial Health Inequalities in the United States. International Journal of Health Services 41:2, pages 231-238.
Crossref
Crossref
Nigel D. Toussaint, Grahame J. Elder & Peter G. Kerr. (2010) A Rational Guide to Reducing Fracture Risk in Dialysis Patients. Seminars in Dialysis 23:1, pages 43-54.
Crossref
Crossref
Gary H. Lyman, Anjana Lalla, Richard L. Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics 31:5, pages 1092-1104.
Crossref
Crossref
Scott D. Ramsey, Zhimei Liu, Rob Boer, Sean D. Sullivan, Jennifer Malin, Quan V. Doan, Robert W. Dubois & Gary H. Lyman. (2009) Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy. Value in Health 12:2, pages 217-225.
Crossref
Crossref